AI hallucinations are often described as unpredictable failures—or as evidence that generative AI can’t be trusted in regulated environments.  That interpretation is understandable, but incomplete.  In reality, hallucinations occur because large language models generate text based on probability, not verification. They are a predictable result of how AI systems express confidence when certainty is unavailable. Once that’s understood, hallucinations become easier to anticipate

If you’ve ever watched an AI tool do a solid job drafting a section—only to cut off a table, ignore an earlier definition, or unravel at the end—you’ve probably assumed the issue was the prompt.  Often, it isn’t.  In many cases, the underlying issue is tokenization, a foundational machine learning concept that directly affects how generative AI processes medical and regulatory documents. Tokenization determines how text is broken down, how much context an AI model can retain,

The FDA’s new announcement, Flexible Requirements for Cell and Gene Therapies to Advance Innovation , signals a notable shift in how regulators are thinking about manufacturing controls during early- and mid-stage development of cell and gene therapies (CGTs). The intent is clear: reduce unnecessary friction, lower barriers to clinical entry, and accelerate innovation for therapies often targeting serious or life-threatening diseases.  At the heart of the guidance are two sta

In clinical documentation software integration, the promise of “plug-and-play AI” has become a siren’s call; just as it is said sailors were lured by the siren’s song only to encounter hidden dangers, clinical teams enticed by the promise of effortless AI integration often discover unforeseen complexities beneath the surface. Vendors often promise effortless automation and streamlined drafting powered by pretrained algorithms that can slot seamlessly into existing workflows—e

The promise of AI-assisted writing in clinical documentation often evokes visions of blazing efficiency and seamless workflows. But beneath the surface lies a stubborn bottleneck that even the most sophisticated algorithms cannot erase: the manual handoffs between authors, reviewers, and disparate systems. This hidden friction point isn’t just a minor inconvenience; it is a systemic tax on time and quality that disrupts the very efficiencies AI aims to unlock and can lead to

Learn how RAG, CAG, and KAG enhance AI in medical writing by improving accuracy, consistency, and compliance. Discover where each fits in regulatory documentation and how Synterex supports explainable automation through AgileWriter.ai®.

The FDA’s latest innovation signals reveal how regulatory systems are evolving—and what FDA regulatory innovation may increasingly require from industry.

In today’s high-stakes biopharma environment, speed, compliance, and precision define success. For regulatory and medical-writing teams, optimizing submission-ready content is no longer just operational—it’s strategic. With AI-powered regulatory documentation systems, companies can align earlier with submission requirements, anticipate reviewer expectations, and dramatically reduce rework and costly delays. The result: accelerated approvals, extended runway, and preserved opp

Discover how EMA and FDA are transforming from reviewers to data-platform operators—and how sponsors and writers must adapt to real-time evidence exchange and continuous review.

Explore the real costs, risks, and ROI of building versus buying an AI-powered regulatory documentation system—and why a hybrid approach often wins

Understanding AI Technologies AI technologies have made significant strides in recent years. Generative AI, in particular, has changed how we approach various tasks. From content creation to data analysis, AI is becoming an indispensable tool. However, to maximize its potential, we must understand the nuances of its operation. The Importance of AI in Biotech and Pharma In the biotech and pharmaceutical sectors, AI can streamline processes, enhance accuracy, and improve compli

Learn how Synterex helps biotechs turn regulatory uncertainty into advantage through expert strategy, automation, and AI-enabled efficiency.

Generative AI is rapidly making its mark in professional writing, but a critical question remains: is it actually doing the work, or...

In the rush to adopt artificial intelligence, many teams are tempted by the promise of “one-click” solutions that claim to transform...

AI-enabled medical writing significantly streamlines the clinical documentation process, but common pitfalls can reduce its...

Recent research from Microsoft  offers one of the most comprehensive looks yet at how generative AI is already reshaping work activities...

Once Upon a Prompt  In academic and clinical research, time is a precious commodity—and so is clarity. With artificial intelligence (AI) writing tools evolving at breakneck speed, researchers and medical writers are now asking a vital question:  How far can AI take us in crafting better, faster manuscripts?  The answer lies in the growing integration of AI-powered writing assistants and the complex terrain of ethics, journal policies, and return on investment (ROI).  Let’s lo

Discover how AI and structured content management are transforming regulatory submissions—boosting speed, consistency, and compliance in health authority interactions.

The FDA’s recent Evaluation of Labeling Submissions with AI (ELSA) pilot program has generated both curiosity and skepticism in the regulatory community. Early responses from reviewers using ELSA have been mixed, with some finding it helpful for catching inconsistencies or typos, while others found it redundant or disconnected from their workflows. While the effort is laudable, the ELSA pilot highlights deeper limitations in how general-purpose AI tools perform in complex, re

Integrating technology-assisted content reuse into medical writing can reduce stress for writers by preventing unnecessary rework and maintaining consistent document quality and compliance. This ensures timely delivery of important new therapies to the patients who need them.